* Apyx Medical Corp is expected to show a fall in quarterly revenue when it reports results on November 8 for the period ending September 30 2024
* The Clearwater Florida-based company is expected to report a 5.0% decrease in revenue to $11.378 million from $11.98 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Apyx Medical Corp is for a loss of 19 cents per share.
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Apyx Medical Corp is $2.50, above its last closing price of $1.17.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.20 -0.20 -0.19 Beat 4.1
Mar. 31 2024 -0.22 -0.21 -0.22 Missed -2.6
Dec. 31 2023 -0.20 -0.18 -0.28 Missed -57.7
Sep. 30 2023 -0.12 -0.11 -0.13 Missed -14.8
Jun. -0.07 -0.07 -0.11 Missed -58.5
30 2023
Mar. 31 2023 -0.16 -0.13 -0.10 Beat 25.9
Dec. 31 2022 -0.15 -0.14 -0.17 Missed -19.3
Sep. 30 2022 -0.15 -0.14 -0.17 Missed -17.2
This summary was machine generated November 6 at 14:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。